Condition: Glycogen Storage Disease Type II, Adult · Sponsor: Assistance Publique - Hôpitaux de Paris
The project is a prospective study in which patients affected by adult-onset Pompe disease with c.-32-13T\>G mutation in the GAA gene will be followed-up during two years to describe the natural history using clinical, imaging, histological and molecular parameters. Secondary objectives are: * To identify biomarkers for assessing efficacy of future therapies based on correcting aberrant alternative splicing in Pompe patients with c.-32-13T\>G mutations. * To determine effectiveness of antisense oligonucleotide chemistries to restore full length GAA transcripts, GAA protein and GAA enzyme activity in fibroblasts and myoblasts obtained from skin and muscle biopsies as well as leucocytes of Pompe patients with c.-32-13T\>G mutations.
This description comes directly from the study's public registry record.
Helge Amthor, MD, PhD · + 33 1 47 10 78 90 · helge.amthor@aphp.fr
Pascal Laforêt, MD, PhD · + 33 1 47 10 37 76 · pascal.laforet@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital Raymond Poincaré | Garches, Hauts-de-Seine, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03564561